How do the experiences and beliefs of adults and children with heterozygous familial hypercholesterolaemia influence their adherence to treatment?:A systematic review of qualitative evidence protocol by Kinnear, Fiona J et al.
                          Kinnear, F. J., Perry, R., Searle, A., Hamilton-Shield, J. P., & Lithander, F.
E. (2018). How do the experiences and beliefs of adults and children with
heterozygous familial hypercholesterolaemia influence their adherence to
treatment? A systematic review of qualitative evidence protocol. Systematic
Reviews, 7, [120]. https://doi.org/10.1186/s13643-018-0793-7
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1186/s13643-018-0793-7
Link to publication record in Explore Bristol Research
PDF-document
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
PROTOCOL Open Access
How do the experiences and beliefs of
adults and children with heterozygous
familial hypercholesterolaemia influence
their adherence to treatment? A systematic
review of qualitative evidence protocol
Fiona J. Kinnear1,2* , Rachel Perry1,2, Aidan Searle1,2, Julian P. Hamilton-Shield1,2 and Fiona E. Lithander1,2
Abstract
Background: Heterozygous familial hypercholesterolaemia (FH) is a genetic disorder characterised by elevated levels
of low density lipoprotein (LDL) cholesterol from birth, estimated to affect 1 in 250 of the UK population. Left untreated,
FH substantially increases an individual’s risk of premature coronary heart disease (CHD) and associated mortality. This risk
can be minimised with timely diagnosis and successful treatment with medication and lifestyle changes, as advocated in
national and international guidelines. Despite these recommendations, the limited research available suggests adherence
to treatment may be sub-optimal. This review will identify and synthesise the available qualitative research regarding the
experiences and beliefs of adults and children with FH in relation to their condition and its treatment, and the influence
of these upon treatment adherence.
Methods: The following electronic databases will be searched from their inception: Cochrane library, MEDLINE, Embase,
PsycINFO (via OVID) and CINAHL. Studies available in English and reporting primary qualitative data will be included.
Database searching will be supplemented with searches in relevant specialist websites. The references of identified papers
will also be hand searched. Two reviewers will independently screen titles and abstracts of identified studies, with full
texts of potentially relevant papers retrieved for review against pre-defined inclusion and exclusion criteria. The Critical
Appraisal Skills Programme (CASP) Qualitative Research checklist will be used to assess quality of the included studies, and
the results will be taken into consideration when reporting the findings. A data extraction tool will be created for use in
this review to extract study findings relevant to the review questions. A thematic synthesis approach will be taken to
analyse the results.
Discussion: Adherence to treatment recommendations is crucial for the successful management of FH and subsequent
decrease in risk of CHD later in life. Common identified themes could provide an understanding of the beliefs and
experiences which influence adherence to treatment recommendations and provide an insight into perceived barriers
and facilitators. The findings are intended to be used in the development of future interventions or guidelines regarding
treatment of children and adults with FH.
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Background
Familial hypercholesterolaemia (FH) is an autosomal
dominant hereditary disorder, characterised by markedly
elevated levels of low-density lipoprotein (LDL) cholesterol
from birth [1]. This review will focus on heterozygous FH
(henceforth to be known as FH) which has been estimated
to affect 1 in 250 of the UK population [2] and substan-
tially increases risk of premature coronary heart disease
(CHD) and associated mortality [3, 4]. However, this risk
can be reduced with appropriate lifelong treatment [5]. UK
and international guidance recommends that individuals
with FH should commence life-long lipid-lowering drug
therapy from 10 years of age, alongside the adoption of
lifestyle advice which aims to encourage maintenance of a
healthy weight, smoking avoidance, participation in regular
physical activity (PA), limited alcohol consumption and
adherence to a healthy, balanced diet [6, 7].
There are very little data regarding medication and
lifestyle advice provision and adherence in the FH popu-
lation [8]. From the available evidence, it appears that
healthcare professionals are following the guidelines with
the majority of adults [9], but treatment provided to chil-
dren is inconsistent [4, 10]. While adherence to medication
in adults appears to be high [11–13], a Dutch question-
naire survey found that only 49% of adults with FH adhere
to dietary and PA recommendations [11]. Similarly, the
adoption of lifestyle recommendations has been reported
to be low in children [10].
Qualitative research can provide an insight into an
individual’s understanding, perceptions and beliefs of
their condition and its management. This can enable the
development of an understanding of how and why indi-
viduals’ display certain behaviours and an awareness of
factors influencing their decisions to adhere to treatment
[14]. Illness perceptions and beliefs about treatment have
been found to influence treatment compliance in adults
with chronic conditions such as asthma [15, 16], epilepsy
[17] and hypertension [18]. Specifically, necessity and
concern beliefs have been found to be modifiers of treat-
ment adherence across a range of health conditions [19].
Similar findings have been found for children and ado-
lescents with asthma [20], cystic fibrosis [21] and type 1
diabetes [22]. Within the FH population, adherence to
treatment has been found to be influenced by several
factors including knowledge of FH [23], perception of
risk [24], beliefs about influence of treatment upon
long-term health [23] and personal experiences such as
family history of cardiovascular disease [25]. Furthermore,
barriers to adhering to treatment have been highlighted
including a lack of motivation [23], social acceptance [24]
and concerns regarding medication [26]. From the limited
research conducted in young adults with FH, experiences
of family history of disease has been found to influence
decisions regarding treatment [25] and lack of credible
information, motivation and symptoms highlighted as
barriers to adhering to treatment [25, 27].
Results from these individual studies provide useful
insights but are restricted by their small sample sizes
and are subject to bias resulting from the researcher’s
interpretation of the participants’ views, and the quotes
they select to present in the findings. By conducting a
systematic review of qualitative studies, a wider range of
patient perceptions and experiences can be examined
which allows for common themes to be identified and
explored in more depth [28]. Furthermore, it could provide
awareness of common enablers and barriers to treatment
adherence within the patient population group. These
findings would be useful in the development of future
interventions or recommendations for the FH population.
To date, one systematic review of qualitative research in
the FH population has been carried out [29]; however, it
aimed to answer questions regarding the influence of
screening approaches on diagnostic rates. Thus far, no
synthesis of qualitative data regarding the experiences
and beliefs of individuals with FH in relation to their
condition, its treatment and the influence of these upon
treatment adherence has been carried out.
Research objective
This systematic review aims to identify and synthesise the
available qualitative evidence regarding the experiences
and beliefs of adults and children with FH in relation to
their condition, its treatment and the influence of these
upon treatment adherence. This review also seeks to
identify any perceived enablers and barriers to treatment
adherence. The findings are intended to be used in the
development of future interventions or guidelines tar-
geting medication and lifestyle behaviours in children
and adults with FH.
Research questions
In adults and children with FH:
 What are the experiences and beliefs of individuals’
in relation to their condition, its associated
morbidity and mortality risk and treatment?
 How do these experiences and beliefs influence
individuals’ adherence to pharmacological and
lifestyle treatment recommendations?
 Are there any enablers and/or barriers to adhere to
pharmacological and lifestyle treatment
recommendations?
 Do the findings differ between adults and children?
Methods
Where appropriate for qualitative reviews, the reporting
of this protocol is in accordance with the ‘Preferred
Reporting Items for Systematic Review and Meta-Analysis
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Protocols (PRISMA-P) 2015 checklist’ [30]. A com-
pleted checklist for this review protocol is available in
Additional file 1. This protocol will also be reported in
accordance with the enhancing transparency in report-
ing the synthesis of qualitative research (ENTREQ)
statement [31].
Eligibility criteria
Papers reporting studies that meet the following criteria
will be included in the analysis.
Participants
The participants include individuals aged ≥ 10 years with
clinically diagnosed FH. In this review, a genetic diagno-
sis of FH is not required for inclusion if the study clearly
states that the study population has all received a clinical
diagnosis. The age of 10 years was used as a cutoff as
this is age that children with FH are currently advised to
be considered for treatment with statins and to attend
subsequent follow-up appointments in a FH specialist
clinic in the UK [7]. Individuals with a history of cardio-
vascular heart disease will be included. Individuals with
a diagnosis of homozygous FH will be excluded.
Phenomena of interest
This review will consider any studies that investigate the
experiences and beliefs of individuals with clinically di-
agnosed FH in relation to their condition, its associated
morbidity and mortality risk and recommended pharma-
cological and lifestyle change treatment. Studies focusing
on specific elements of FH which are unrelated to the
research objectives of this report, such as attitudes towards
genetic testing, will be included if the study also includes
findings relevant to this review which can be independ-
ently extracted. Studies in which the focus is upon the
perceptions and experiences of the family members, for
example, parents of children and adolescents with FH,
will also be included.
Type of studies
This review aims to explore the experiences and beliefs of
individuals which are most appropriately done through
analysis of qualitative data, and as such, only qualitative
studies that report primary data will be included. For the
purpose of this review, qualitative research refers to
studies in which widely recognised qualitative methods of
data collection and data analysis have been used. This
includes, but is not limited to, data collection methods
such as focus groups and interviews, and data analyses
methods including narrative analysis and grounded theory
[32]. Only studies in which the full text is available in
English will be eligible for inclusion. This decision was
taken due to the potential problems in interpreting and
translating qualitative data in another language by the
research team and lack of resource to carry this out.
Mixed method studies, in which both quantitative and
qualitative methods were used, will be included if it is
possible to extract only the qualitative data. Quantitative
studies, commentaries or reviews on the subject will be
excluded. Studies which exclusively collected information
through self-reported questionnaires or researcher admin-
istered surveys will be excluded as this does not allow for
an in-depth understanding of individuals’ beliefs.
Intervention/exposure
In this review, treatment is defined as any action taken
by individuals with FH in an attempt to manage their
condition as a result of their own knowledge of the con-
dition, advice given to them by a healthcare professional
or from other family members. This includes, but is not
limited to, behaviours relating to medication, weight
management, smoking, diet and physical activity. Variations
in the length of time since diagnosis and the mode of
delivery, intensity and content of treatment advice which
individuals will have received are expected; however, no
exclusions will be made based on this criteria.
Setting
Studies will be included regardless of the country in
which they were conducted and the setting in which the
qualitative data were collected from individuals.
Search strategy
The search will be systematic, pre-planned and comprehen-
sive in order to find all available studies, as recommended
for thematic synthesis [31, 33]. The search strategy will be
developed by two reviewers (FK, RP) with reference to the
available guidance and recommendations [31, 34, 35], as
well as consultation with an information specialist with pre-
vious experience in designing qualitative search strategies.
It will be carried out by one reviewer (RP).
Electronic searches
Literature searches will be undertaken in the following
databases for published articles: MEDLINE, Embase,
PsycINFO (via OVID), Cochrane library and CINAHL.
All will be searched from the inception of the database
to present. Search terms relating to the population will
be combined with a validated search filter [36] containing
terms relating to qualitative methods and methodology.
The search will use a combination of subject headings
(e.g. MeSH) and text words. A draft of the search
strategy intended for use in MEDLINE is available in
Additional file 2. The same search strategy will be used
in the other listed databases, with appropriate subject
headings and database-specific modifications to syntax
and qualitative search filter applied.
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Searching other resources
The reference lists of all included studies will be hand
searched for additional studies. As qualitative research is
often found in grey literature such as conference abstracts
and theses [31], the OpenGrey database will be searched.
Relevant specialist websites, including charities and
government health departments with a focus in lipid, cardiac
or genetic disorders will also be searched, e.g. American
Heart Association, the international FH Foundation, the
British Heart Foundation and the Simon Broome Register.
Authors of any identified abstracts will be contacted to
establish if full text is available. Experts in the area will be
contacted to enquire about the existence of any unpublished
work.
Data management
The search results will be managed using Endnote refer-
ence management software. The results from the database
searches will be imported into an Endnote library, with
duplicates removed during the screening of the data.
Selection of studies
Two reviewers (FK, RP) will independently screen the
titles and abstracts of all retrieved records for inclusion.
Full-text copies of potentially relevant studies will be
retrieved for in-depth review against the inclusion criteria.
The full-text articles will be screened independently by
two reviewers (FK, JHS). Explanations for exclusion will
be recorded at the full-text stage. A Preferred Reporting
Items for Systematic Review and Meta-Analysis (PRISMA)
flow chart will be produced to illustrate the different
stages of study selection. Full-text articles which are
judged to meet inclusion criteria will be taken forward
to appraisal and data extraction stages.
Data extraction
Firstly, the contextual and methodological information
of the included studies will be extracted into a study
table designed for this review, as recommended [34].
Information on the following will be extracted:
 Publication information: author, year of publication,
country of study
 Sample characteristics: number of participants,
demographics, FH diagnostic criteria
 Study design: methodological approach, conceptual
bases underlying study, analysis method, setting
 Study objectives or aims
Secondly, in line with Thomas and Harden’s approach
[33], study findings (data) will be extracted using a tool
designed specifically for this review. All text and quotations
reported in the ‘results/findings’, ‘discussion’ and ‘conclu-
sion’ sections of papers, as well as in any supplemental files
provided by the authors, will be considered for extraction.
This inclusive approach to data extraction has been taken
to minimise risk of missing findings which may be of
potential value to the synthesis, as it is recognised that
authors may report useful data out with the ‘findings’
section [34]. Any data judged to be relevant to the
research questions of this review will be extracted. This data
will take the form of first-order constructs (participants’
quotes and author summaries of quotes) and second-order
constructs (author’s interpretations).
Both stages of data extraction will be carried out inde-
pendently by two reviewers (FK, AS), with any disagreement
resolved by discussion until consensus is reached, with a
third reviewer (FL) consulted if required. The data extrac-
tion tool will be piloted on the first five studies, after which
its suitability for use will be discussed and any required
amendments made before continuation of data extraction
on the remaining studies. Microsoft Excel or NVivo
software will be used to manage the extracted data.
Critical appraisal of study quality
The Critical Appraisal Skills Programme (CASP) Qualitative
Research Checklist [37] will be used to assess the meth-
odological validity of included studies. This will be carried
out by two reviewers (FK, AS), with any disagreements
discussed with a third reviewer (RP or FL). This tool was
chosen as it can be applied to qualitative research of
various designs, is frequently used in the literature [31]
and is a recommended tool [34].
To avoid the possibility of excluding potentially valuable
insights that can be generated from qualitative studies
assessed to be inadequately designed or reported [28], the
results of the appraisal will not be used to exclude any
study. In their worked example of thematic synthesis
methodology, Thomas and Harden [33] chose not to
exclude studies as there is no widely accepted and empir-
ically tested method for excluding studies based on their
quality. However, it is recommended that the quality of
included studies should be critically analysed in the subse-
quent data synthesis and be considered when drawing
conclusions in systematic reviews of qualitative research
[31]. Therefore, the appraisal findings will be presented
alongside the findings of the review. Furthermore, after
synthesis, the relative contributions of studies to the
derived analytic themes and any recommendations
which are made based on these will be explored in relation
to their evaluated quality.
Data synthesis
There are many recognised methods for qualitative syn-
thesis, with no gold standard method recommended for
use [38]. Instead, it is advised that the choice of method
should be informed by the type and scope of review
question and the content of the available literature [34].
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Thematic synthesis is a method developed by Thomas
and Harden [33] to answer questions addressing the suit-
ability and acceptability of health promotion and public
health interventions. The benefit of including the experi-
ences and perceptions of the individuals being targeted in
the interventions when assessing the effectiveness of such
interventions was recognised, and thematic synthesis was
developed to analyse and understand these qualitative
data. The comparable research aims of this review, and
its recommendation for use in qualitative systematic reviews
[34], led to the decision to choose thematic synthesis.
Thematic synthesis is comprised of three main stages—
line by line coding, development of descriptive themes
and generation of new analytical themes from consider-
ation of all the available data [33]. Line by line analysis will
be carried out on the extracted data, with each first or
second order construct identified being assigned codes.
These codes will be inductively created in response to the
findings uncovered. This will be carried out independently
by two reviewers (FK, AS) with a third reviewer (FL)
consulted to resolve any disparities. The two reviewers
(FK, AS) will then work in collaboration to develop initial
descriptive themes and categories based upon the raw data
that closely reflect the aggregative findings of the included
studies. Lastly, interpretative analytical themes based upon
these aggregative findings will be generated where possible
by the two reviewers. This stage seeks to go beyond the
original findings of the studies to generate additional
understanding and aims to produce recommendations
for future interventions.
Discussion
Adherence to treatment recommendations is crucial for the
successful management of FH and subsequent reduction in
risk of CHD later in life. This review will summarise the
available qualitative evidence regarding the experiences and
beliefs of adults and children with FH in relation to their
condition and its treatment. Common identified themes
could provide a greater understanding of the beliefs and ex-
periences which influence the extent to which individuals
follow current treatment recommendations and provide an
insight into perceived barriers and facilitators to adherence.
The findings are intended to be used in the development of
future interventions or guidelines targeting medication and
lifestyle behaviours in children and adults with FH.
Additional files
Additional file 1: PRISMA-P (Preferred Reporting Terms for Systematic
Review and Meta-analysis Protocol(s) 2015 checklist: recommended items to
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Additional file 2: Draft MEDLINE search strategy. (DOCX 14 kb)
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